Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04629703 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
SARS (Severe Acute Respiratory Syndrome)
SARS Pneumonia
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Pneumonia
Pneumonia, Viral

Interventions

DRUG: Fostamatinib
DRUG: Placebo

Sponsor

Rigel Pharmaceuticals